memantine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 111 Diseases   73 Trials   73 Trials   1509 News 


«12...25262728293031323334353637»
  • ||||||||||  memantine / generics
    Journal:  Modern views on gait impairment in Parkinson`s disease and its correction (Pubmed Central) -  May 18, 2019   
    Attention is drawn to the fact that the use of memantine hydrochloride (akatinol memantine) is a promising direction for gait impairment correction in the advanced and late stages of PD due to the improvement of glutamatergic transfer from the striatum to the specific areas of the cerebral cortex involved in gait control. The results of the latest clinical trials are analyzed.
  • ||||||||||  donepezil / generics, memantine / generics, rivastigmine / generics
    Clinical, Journal:  Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease patients treated with medication. (Pubmed Central) -  May 15, 2019   
    The data may provide clinicians with information regarding to the cognitive decline rate in every year while their AD patients receive approved pharmacological therapy in real-world practice. Increasing age and severe of dementia when receiving therapy are the main factors that associated with faster deterioration.
  • ||||||||||  memantine / generics
    Journal:  Ginkgolide A prevents the Aβ-induced depolarization of cortical neurons. (Pubmed Central) -  May 7, 2019   
    This pure compound improves the memory of wild type mice. Our findings indicate that ginkgolide A has great potential clinically for the treatment of AD because it might target NMDA receptors just like memantine.
  • ||||||||||  memantine / generics
    Clinical, Journal:  Clinical Benefit of NMDA Receptor Antagonists in a Patient WithGene Mutation. (Pubmed Central) -  May 7, 2019   
    He was started on N-methyl-D-aspartate receptor antagonists (memantine and dextromethorphan), as well as coenzyme QOne year later, he showed significant improvement in sustained attention, learning efficiency, general cognitive efficiency, and fine motor dexterity. We postulate that N-methyl-D-aspartate receptor antagonists were effective for behavioral, cognitive, and cerebellar symptoms in our patient withgene mutation.
  • ||||||||||  memantine / Generic mfg., escitalopram / Generic mfg.
    Trial completion, Trial completion date:  Brain Aging and Treatment Response in Geriatric Depression (clinicaltrials.gov) -  Apr 20, 2019   
    P4,  N=110, Completed, 
    Topiramate, lamotrigine, aripiprazole, olanzapine, risperidone, memantine, and quetiapine are alternative augmentation drugs; however, a definitive conclusion of the best drug remains undetermined because of the considerable heterogeneity and limited numbers of studies and patients for each agent. Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Jan 2019
  • ||||||||||  memantine / generics
    Preclinical, Journal:  Memantine treatment of juvenile rats with kaolin-induced hydrocephalus. (Pubmed Central) -  Apr 19, 2019   
    Glial fibrillary acidic protein (GFAP) content was higher in the low dose memantine group compared to vehicle-treated group, but there were no differences in GFAP-immunoreactive astrocytes or Iba-1- immunoreactive microglia between groups. Memantine therapy stabilized ventricular expansion and improved some behavioral measures but did not reduce brain tissue changes in juvenile rats with kaolin-induced hydrocephalus.
  • ||||||||||  memantine / generics
    Review, Journal:  Memantine for dementia. (Pubmed Central) -  Apr 18, 2019   
    There is a small clinical benefit of memantine in people with moderate-to-severe AD, which occurs irrespective of whether they are also taking a ChEI, but no benefit in people with mild AD.Clinical heterogeneity in AD makes it unlikely that any single drug will have a large effect size, and means that the optimal drug treatment may involve multiple drugs, each having an effect size that may be less than the minimum clinically important difference.A definitive long-duration trial in mild AD is needed to establish whether starting memantine earlier would be beneficial over the long term and safe: at present the evidence is against this, despite it being common practice. A long-duration trial in moderate-to-severe AD is needed to establish whether the benefit persists beyond six months.
  • ||||||||||  memantine / generics
    Journal:  EXPERIMENTAL STUDY OF PAIN-RELIEVING MECHANISMS OF 4-[4-OXO-(4H)-QUINAZOLIN-3-YL]-BENZOIC ACID (PK-66 COMPOUND). (Pubmed Central) -  Apr 17, 2019   
    At the same time, increased antinociception with underlying Memantine administration preceding PK-66 was observed only in the first hours of the experiment. Therefore, the studies conducted have shown that the adrenergic system, in particular alpha-2 adrenergic receptors, dopaminergic and GABAergic systems, is involved in the mechanisms of analgesic action of 4-[4-oxo-(4h) -quinazolin-3-yl]-benzoic acid (PK-66) without any effect of PK-66 on opioid receptors.
  • ||||||||||  memantine / Generic mfg.
    Trial completion date, Trial primary completion date:  Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy (clinicaltrials.gov) -  Apr 16, 2019   
    P1,  N=25, Recruiting, 
    Furthermore, activation of Sxc may compensate for the cognitive impairments that are induced by hyperactivation of thalamocortical glutamatergic transmission following activation of Sxc/II-mGluR in the MDTN and Sxc/II-mGluR/III-mGluR in the mPFC. Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  memantine / Generic mfg.
    Trial completion date, Trial primary completion date:  Effect of Memantine on Radiotherapy-related Cognitive Impairment (clinicaltrials.gov) -  Apr 12, 2019   
    P2/3,  N=240, Recruiting, 
    Since the FDA-approved NMDAR antagonists memantine and ifenprodil showed differential radiosensitizing effects, these compounds may constitute novel optimizations for therapeutic interventions in glioblastoma. Trial completion date: Dec 2018 --> Dec 2024 | Trial primary completion date: Dec 2018 --> Oct 2024
  • ||||||||||  memantine / Generic mfg.
    Biomarker, Trial initiation date:  Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease (clinicaltrials.gov) -  Apr 12, 2019   
    P4,  N=88, Recruiting, 
    Trial completion date: Dec 2018 --> Dec 2024 | Trial primary completion date: Dec 2018 --> Oct 2024 Initiation date: Jan 2018 --> Jan 2019
  • ||||||||||  Galvus (vildagliptin) / Novartis
    Preclinical, Journal:  Vildagliptine protects SH-SY5Y human neuron-like cells from Aβ 1-42 induced toxicity, in vitro. (Pubmed Central) -  Apr 11, 2019   
    However we did not get protective effect of vildagliptine against Aβ toxicity on mitochondrial membrane potential. These results indicate that vildagliptine exerts a protective effect against Aβ by decreasing apoptosis related proteins, lowering GSK3β and Tau phosphorylation levels in addition to expression of PSEN1 and PSEN2 mRNA downregulation effect.
  • ||||||||||  memantine / generics
    Clinical, Journal:  Modern trends in epidemiology of dementia and management of patients with cognitive impairment (Pubmed Central) -  Apr 10, 2019   
    ...This year marks the 20th anniversary of memantine, one of the basic anti-dementia drugs, registration in Russia...Many multi-central studies involving 1250 patients with cognitive impairment were conducted A great number of educational activities, social projects that helped to increase awareness of dementia issues in medical community as well as society in general were implemented. Total screening programs for identification of cognitive impairment are being introduced, psychological support programs for caregivers of dementia patients are being implemented.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Targeting Nicotinic and NMDA Receptors Concurrently: Rocket Science, Common Sense or Game Changer? (Regency S-V) -  Apr 3, 2019 - Abstract #SIRS2019SIRS_140;    
    Hence, this combination could be the first antischizophrenia treatment, improving positive, cognitive, and negative symptoms concurrently with KYNA, mismatch negativity, brain-derived neurotrophic factor, prepulse inhibition, gamma oscillation, and oxidative stress/antioxidant as biomarkers. Hence, an RCT with this combination is warranted.
  • ||||||||||  memantine / Generic mfg.
    Enrollment open:  Memantine for Epileptic Encephalopathy (clinicaltrials.gov) -  Mar 12, 2019   
    P4,  N=30, Recruiting, 
    Thus, a new regimen of GTPm orally administered twice per day attenuated orofacial pain after consecutive 5 days. Not yet recruiting --> Recruiting
  • ||||||||||  memantine / Generic mfg.
    Biomarker, Enrollment open, Trial initiation date:  Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease (clinicaltrials.gov) -  Jan 3, 2019   
    P4,  N=88, Recruiting, 
    Trial completion date: Sep 2023 --> Apr 2023 | Trial primary completion date: Sep 2018 --> Apr 2018 Not yet recruiting --> Recruiting | Initiation date: Nov 2018 --> Jan 2018
  • ||||||||||  memantine / Generic mfg.
    New P4 trial:  Memantine for Epileptic Encephalopathy (clinicaltrials.gov) -  Dec 19, 2018   
    P4,  N=30, Not yet recruiting,